Meropenem - Antibiogram Data

Inpatients (Non-Urinary Isolates)
% of Isolates Susceptible

Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 14.3 % of samples of E.coli, K.pneumoniae and P.mirabilis

Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 14.3 % of samples of E.coli, K.pneumoniae and P.mirabilis

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

Note

  • January 1, 2019 - December 31, 2019

  • R: Intrinsically resistant